Compounds and Clinical Trial Results
The CuraBase database contains information on 100s of compounds. These include FDA approved agents as well as compounds currently underging preclinical or clinical evaluation.
Recently Updated: Sorafenib (Nexavar, Onyx Pharmaceuticals), XL147, XL184, XL765, XL880 (Exelixis), Telatinib (ACT Biotech), CAL-101 (Calistoga Pharm.), Pazopanib (GlaxoSmithKline), CPX-1 (Celator)
Clinical trial results presented at the ASCO 2009 annual meeting:
BSI-201 (BiParsciences) in combination with chemotherapy increases survival in patients with triple-negative breast cancer.
New compounds presented at the 2009 AACR meeting now in the database.
|
Comprehensive Information Related to Individual Cancer Types
Free (no sign up required) access to a catalogue of recurrent molecular aberrations in cancer.
Recently Updated Molecular Aberrations:
PI3 Kinase amplification in non-small cell lung cancer
CuraBase collects information on clinical trials in all malignant diseases.
Recently Added:
A Phase-I study of XL-184 administered orally to patients wtih advanced malignancies, including a subgroup of patients with medullary thyroid cancer (MTC)
Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer
|
